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ABSTRACT  
The use of different definitions for bronchopulmonary dysplasia (BPD) has been an 
on-going challenge. We searched papers published in English from 2010 and 2015 
reporting BPD as an outcome, together with studies that compared BPD definitions 
between 1978 and 2015. We found that the incidence of BPD ranged from 6% to 
57%, depending on the definition chosen, and that studies that investigated 
correlations with long-term pulmonary and, or, neurosensory outcomes reported 
moderate to low predictive values regardless of the BPD criteria. Conclusion. A 
comprehensive and evidence-based definition for BPD needs to be developed for 
benchmarking and prognostic use. 
 
Key Words: Bronchopulmonary dysplasia, Chronic lung disease, Pulmonary insufficiency, 
National Institute of Child Health and Human Development, Quality improvement 
 
Key Notes 
 The use of different definitions for bronchopulmonary dysplasia (BPD) has been an 
ongoing challenge.  
 We found that the incidence of BPD ranged from 6% to 57%, depending on the 
definition chosen, and studies investigating correlations with long-term pulmonary 
and, or, neurosensory outcomes reported moderate to low predictive values regardless 
of the BPD criteria.  
 A comprehensive evidence-based definition for BPD needs to be developed for 
benchmarking and prognostic use. 
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INTRODUCTION 
Bronchopulmonary dysplasia (BPD) is the most common morbidity of surviving 
preterm infants and is associated with adverse long-term pulmonary and 
neurodevelopmental outcomes (1). With advances in perinatal care increasing the survival of 
extremely preterm infants, the incidence of BPD has either remained static or risen in the 
last 20 years (2,3). Given that BPD rates vary depending upon the centre, country and 
population examined, comparisons of its prevalence between studies remains a challenge. A 
major factor contributing to the variation in reported BPD rates is the definitions used to 
classify the condition in neonates. In 2012, a comparative study reported significant 
variabilities in the definitions used to classify outcomes in international data (2), including 
BPD. The use of different definitions hampers comparisons or the ability to synthesise the 
results of drugs trials and other interventions in neonatal practice. These drawbacks highlight 
the need for efforts to harmonise definitions and establish a unified system of classification 
for BPD diagnosis (4,5). 
Since its initial identification in 1967 by Northway et al (6), the criteria and definitions 
used to diagnose BPD have undergone a number of modifications. A number of different 
criteria for BPD have appeared in the literature since then, beginning with definitions 
developed for chronic lung disease (CLD) by Tooley (7) in the late 1970s, to modifications 
made by Shennan et al (8) in the late 1980s (7-11). By the early 1990s, the Neonatal 
Research Network of the American National Institute of Child Health and Human 
Development (NICHD) raised concerns over the wide variation in BPD incidence rates 
reported across its sites. These challenges were later addressed at an NICHD workshop in 
2001, resulting in the proposal for a consensus definition for BPD (12). Despite these efforts, 
variations in definitions used in contemporary BPD clinical research studies to describe BPD 
as a main outcome still exist and are highlighted in Table 1. Therefore, our primary objective 
was to conduct a scoping review of different BPD definitions used in peer-reviewed 
publications between 2010 and 2015 and to determine the variations in definitions used in 
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published studies. Our secondary objective was to review studies that compared different 
definitions of BPD in the same cohort with the explicit intention of comparing definitions and 
to review studies where such comparisons were extended to long-term neonatal respiratory 
and, or, neurodevelopmental outcomes. 
 
METHODS 
Study selection 
We included human-based studies that listed BPD, CLD or prematurity-related 
respiratory insufficiency as either a primary or a secondary outcome. This encompassed 
randomised controlled studies, retrospective and prospective cohort studies, case-control 
studies, case-series, pre-post design, cross-sectional and questionnaire design studies. We 
excluded survey design studies using unclear definitions to describe BPD in participants, as 
well as animal and in vitro studies. We also excluded studies that evaluated the 
diaphragmatic hernia population, as it is a special condition-related situation. Studies that 
were only reported as protocols were also excluded from our analysis. 
For the secondary objective, we included studies that used two or more definitions of 
BPD in the same population, with the explicit purpose of comparing definitions. We also 
collected information on incidences or correlation or diagnostic statistics related to either 
long-term respiratory or neurodevelopmental outcomes in infancy or childhood, if available.  
 
Search strategy 
With the help of an experienced librarian, we searched the PubMed database to 
identify eligible studies for both objectives. For the primary objective, the search was 
confined to studies published between 2010 and 2015. For the secondary objective, we 
included studies published between 1978 and 2015, in order to capture all the eligible 
studies that compared at least two definitions of BPD and their respective predictive ability 
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for adverse long-term outcomes. For both objectives, the studies were limited to those 
published in English. The detailed search strategy and identified literature is reported in 
Appendix 1.  
 
Data collection 
All eligible studies identified from the initial search underwent title and abstract 
screening by one reviewer (DH), followed by a full-text review of potentially relevant articles 
by two reviewers (DH and PS). Any differences noted between the two reviewers were 
resolved by consensus. After a full-text review, data were extracted from all selected studies, 
including: the year of publication, country of origin, whether it was a single or multicentre 
study), whether a definition of BPD was listed, whether BPD was a primary outcome, the 
type of definition - namely a physiological criteria-based definition or a definition that 
included death - and the categorisation of severity of BPD. Studies that compared various 
definitions of BPD were reviewed separately and information on the rates of BPD diagnosis, 
and its correlation with respiratory or neurodevelopmental outcomes, were extracted. 
The review protocol was registered on the International prospective register of 
systematic reviews (PROSPERO), with the registration number CRD42016035931. 
PROSPERO aims to provide a comprehensive listing of systematic reviews registered at 
inception to help avoid duplication and allow researchers to comply with the Preferred 
Reporting Items for Systematic Reviews and Meta-analyses. 
 
RESULTS 
The detailed search results are reported in Figure 1. Of the initial 2,134 papers we 
identified, 820 were included in our review. Of these, 628 (77%) reported a definition for 
BPD, whereas 192 (23%) failed to provide a definition despite reporting BPD as an outcome.  
 A comparison of the baseline characteristics of the studies that defined BPD versus 
those that failed to provide a definition is outlined in Table 2. There were no differences 
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between studies reporting a definition or not with regards to the continent of the study, 
whether it was a single or multicentre study and the year of publication. The definition was 
more likely to be clearly documented in case series and case control and cross-sectional 
studies than in clinical trials or cohort studies. Of the studies in which BPD was chosen as 
the primary outcome, 17% did not define the criteria used. 
Table 3 describes various characteristics of the studies that defined BPD. Overall, 
45% of papers reported the Shennan et al (8) definition, whereas 30% used the NICHD 
consensus definition (12). The use of  a physiological definition such as an oxygen challenge 
test (11) was reported in approximately 6% of the papers reviewed. Only 5% of the studies 
contained information on whether neonates who died before meeting the criteria for BPD 
cut-offs – such as 28 days of age or 36 weeks post menstrual age - were included in the 
denominator. The severity of BPD was defined in 30% of the reports and of these, BPD was 
classified as mild, moderate or severe in 132 studies (70%), as moderate or severe in 28 
(15%), as severe in only 18 (10%) and as mild or moderate in one study (<1%). Different 
types of classifications were used in eight (4%) of the studies and one study categorised the 
severity without providing a description. 
 The findings of the secondary objectives are reported in Tables 4 and 5. There were 
11 studies that explicitly compared at least two definitions of BPD in the same cohort of 
neonates and, of these, five reported on the correlations between definitions and infantile or 
childhood respiratory or neurodevelopmental outcomes. Marked variations in the rate of BPD 
were identified depending upon the definition and denominator population used, including 
just the neonates who survived,  all the eligible neonates in the studies, irrespective of early 
death and just the eligible neonates that there was data for. Overall, the rates of BPD were 
higher when Tooley (7) or Bancalari et al (9,13) definitions were applied, than when the 
Shennan et al definition was used (8). Furthermore, a comparison of the Shennan et al (8) 
and the NICHD consensus definitions (12) also demonstrated variable rates based upon the 
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denominator population. However, the differences between the definitions in predicting long-
term outcomes were minimal. 
 
DISCUSSION 
In the five decades since it was first described, the definition or characterisation of 
BPD has undergone several iterations (6,9,12,14-16). This scoping review presents these 
various modifications and forms of BPD definitions, in addition to their frequency of use in 
publications. Our review confirms that published reports are still highly variable in terms of 
BPD definitions. Approximately, one-quarter of the papers did not define BPD despite the 
inclusion of morbidity as an outcome in their studies. Meanwhile, a significant relationship 
was noted between study types and whether a definition for BPD was reported or not. 
Approximately half of the reports that defined BPD used the definition outlined by Shennan 
et al (8), whereas one-third of the reports either used the NICHD definition or its modified 
version (12). The proposed physiologic definition, such as an oxygen challenge test (11), 
was used in a very small number of reports with marked variability. In the majority of studies, 
it was unclear how the denominator was selected to calculate BPD incidence with respect to 
death or discharges occurring before the specified cut-off criteria. Moreover, marked 
differences in the rate of BPD were observed in the same study cohort when different 
prepositions within the definitions were used, such as at or for or on. For example, the 
NICHD (12) criteria are ambiguous and the original specification regarding receipt of oxygen 
for 28 days has since been misinterpreted as receiving oxygen at 28 days in many reports. 
Comparisons of BPD definitions revealed that these definitions had low to moderate 
predictive values in terms of abnormal pulmonary or neurological outcomes in early 
childhood. 
To our knowledge, our review was the first to assess the variability of BPD definitions 
reported in all types of peer-reviewed publications. The major strengths of this scoping 
review included the comprehensive selection of studies published in the last six years, the 
large number of studies included and the attempt to identify nuances associated with 
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different nomenclatures of BPD. This review permitted the extraction of data from a wide 
selection of study designs, while allowing the narrative integration of the relevant evidence. 
We intended to keep this as a scoping review as our purpose was to be more exploratory in 
addressing the question of what rather than how. We neither assessed the quality of the 
included studies nor collected data on the rate of BPD from each study, because the 
baseline population varied too much between studies to draw any meaningful conclusions. 
Another limitation of this review was the selection of only English language studies from one 
database, as it would not have been practically feasible to cover many languages and 
databases on this topic. 
A systematic review of randomised controlled trials of agents for preventing BPD that 
was published between 1992 and 2014 reported that the definition described by Shennan et 
al (8) was the most commonly used, in 71% of trials, followed by that of Bancalari et al (9) in 
45% of trials. Interestingly, some trials reported rates using multiple definitions (17). 
However, this review was limited to clinical trials, as variations in other types of studies were 
not explored. The issue of non-comparable BPD definitions has surfaced since the liberal 
use of non-invasive support and the recognition of oxygen-induced and atelectasis-
associated injury in immature lungs. In order to keep alveoli adequately expanded, and to 
avoid oxygen-related lung injury, many neonates are now managed on higher end expiratory 
pressure (10) provided via non-invasive respiratory support. This leads to the reduced use of 
oxygen, at the cost of high end-expiratory pressure. Because they are in room air, these 
infants do not meet the traditional cut-off of the need for oxygen at a specified time. This 
feature defeats the underlying basis for the definition of BPD, which originally aimed to 
identify neonates who had chronic pulmonary insufficiency and were not able to fully support 
their own respiration without assisted support and faced a higher risk of abnormal pulmonary 
and, or, respiratory outcomes (6,9). The NICHD (12) definition addresses this issue by 
classifying neonates that require any positive pressure support at 36 weeks of postmenstrual 
age as having moderate or severe BPD. However, this introduces other uncertainties, 
especially with regard to neonates who are receiving humidified high-flow air via a nasal 
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cannula. In Canada, it was shown that by applying the Shennan et al definition (8), 
approximately 10% of neonates of less than 33 weeks of gestation were excluded from 
having pulmonary insufficiency at 36 weeks, because they were receiving positive pressure 
support but were in room air (18). The Shennan et al (8) definition also has inherent 
limitations regarding applicability, as another study showed that several neonates were 
transferred to step-down units or discharged home before 36 weeks and, therefore, may not 
have been included in the data or may have had imputed data. The inclusion or exclusion of 
neonates discharged before 36 weeks in the denominator can lead to over- or under-
reporting of BPD rates (19). Meanwhile, the criteria proposed by the NICHD (12) are 
ambiguous in that the original specification regarding receipt of oxygen for 28 days has since 
been misinterpreted as receiving oxygen at 28 days in many reports. This subtle change in 
semantics can influence the rate of BPD dramatically (13). For instance, Bancalari and 
Claure (13) reported that being on oxygen for all of the first 28 days classified only 6% of 
neonates as having BPD, whereas oxygen at 28 days categorised 57% of neonates with the 
condition. In addition, the NICHD definition classifies all neonates as having BPD if they are 
on oxygen at or for 28 days. Apart from the additional advantage of classifying neonates as 
mild, moderate and severe categories, this definition is similar to the definition proposed by 
Bancalari (9) in the late 1970s. Thus, it appears that no single definition or criteria used for to 
diagnose BPD is ideal. Our review also raises an important point about whether 
dichotomising BPD at a set cut-off is an appropriate measure or whether the richness of 
continuous data, such as the duration of respiratory support or duration of oxygen therapy 
prior to discharge home, is a better alternative for predicting long-term respiratory and 
neurodevelopmental health. This needs to be addressed in future studies. 
Another important finding of this review was the correlation between definitions and 
pulmonary or neurodevelopmental outcomes during infancy or childhood. Our analysis 
revealed marked differences in the childhood outcomes assessed. It varied from simple, yet 
highly unreliable measures of the use of bronchodilator to neonatal death prior to 
assessment. This underlines the importance of identifying outcomes that are patient-centred 
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and those that affect the quality of life for a child and their caregivers. In addition, none of the 
definitions or cut-offs were significant enough for clinical use.  
The bigger overarching question is how to proceed from here? As a global neonatal 
and perinatal community, we need to achieve a consensus on: (a) the need to identify or 
label a child with a chronic condition, (b) the aim of defining, predicting or identifying chronic 
pulmonary insufficiency of prematurity, (c) the outcomes to be predicted based on certain 
postnatal criteria and (d) the individuals who will determine these predictors and outcomes, 
such as practitioners, other healthcare workers and, or, the parents, as stakeholders. 
Ultimately, the least concern that parents have is whether their child required oxygen at 35 
weeks or 37 weeks. Instead, parents would prefer to see their child healthy, with no residual 
pulmonary and neurodevelopmental consequences of preterm birth. From a practitioner and 
policymaker perspective, it is important to identify children who will require increased use of 
long-term resources, so that preventative secondary and tertiary measures can be 
implemented before a child is discharged from the neonatal unit. Meanwhile, healthcare 
workers would prefer to have interim indicators that they can strive to achieve using different 
clinical care and quality improvement strategies that are measurable, achievable and 
reproducible. Thus, when it comes to pulmonary insufficiency of prematurity it is essential to 
strike a balance between the need for prediction from the policy-makers’ and planners’ 
perspectives, the need for easy interim criterion development from the practitioners’ 
perspective and the need for meaningful outcome detection from the parents’ and 
practitioners’ perspectives associated with. To accomplish this, further efforts should focus 
on the discovery and development of biomarkers for the prediction of future respiratory and 
neurodevelopmental outcomes of preterm neonates. However, until these biomarkers are 
identified we have to use the existing available clinical information in such a way that an 
informative perspective can be gained by considering respiratory status in the interim period 
prior to discharge home. A clearer objective definition of BPD will also provide an opportunity 
for successful preventative and treatment strategies, including potential drug development 
(17).  
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CONCLUSION 
Our review identified marked differences in the use of various definitions for BPD 
across a spectrum of different clinical research study designs. In order to inform and 
establish a consistent definition of BPD in peer-reviewed literature, it is essential to develop 
criteria, by consensus, using data-driven approaches and engaging key stakeholders, 
parents and families. From a research perspective, further evaluation of the prospective and 
retrospective data on childhood respiratory and, or, neurodevelopmental outcomes is 
needed to validate, refute and suggest new cut-offs that incorporate current and 
contemporary respiratory support practices. 
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Figure Legends: 
Figure 1: Flow chart of Bronchopulmonary Dysplasia (BPD) study selection 
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Box 1: Definitions of Bronchopulmonary Dysplasia in Preterm Infants: Review 
Search Strategy 
Search strategy  Results 
Infant, newborn/ or infant, low birth weight/ or 
infant, small for gestational age/ or infant, very 
low birth weight/ or infant, extremely low birth 
weight/ or infant, premature/ or infant, extremely 
premature/ or (low adj3 gestational age).ti,ab. Or 
(small adj3 gestational age).ti,ab. Or 
neonat*.ti,ab. Or premature*.ti,ab. or 
preterm.ti,ab. or low birth weight.ti,ab. or (VLBW 
or ELBW).ti,ab.  
AND 
Chronic lung disease.ti,ab. or bronchopulmonary 
dysplasia/ or bronchopulmonary dysplasia.ti,ab. 
or oxygen inhalation therapy/ut [utilization] or 
continuous positive airway pressure/ or (CPAP or 
continuous positive airway pressure).ti,ab.  
 
Not: exp animal/ not human/ 
Not: limit to (case reports or comment or editorial 
or historical article or letter) 
Limit to (yr=2010-current and English) 
2133 
Infant, newborn/ or infant, low birth weight/ or 
infant, small for gestational age/ or infant, very 
low birth weight/ or infant, extremely low birth 
weight/ or infant, premature/ or infant, extremely 
premature/ or (low adj3 gestational age).ti,ab. Or 
(small adj3 gestational age).ti,ab. Or 
neonat*.ti,ab. Or premature*.ti,ab. or 
preterm.ti,ab. or low birth weight.ti,ab. or (VLBW 
or ELBW).ti,ab. 
AND 
respiratory insufficiency/ or respiratory 
insufficiency.ti,ab.     
 
Not: exp animal/ not human/ 
Not: limit to (case reports or comment or editorial 
or historical article or letter) 
Limit to (yr=2010-current and English) 
245 
Infant, newborn/ or infant, low birth weight/ or 
infant, small for gestational age/ or infant, very 
low birth weight/ or infant, extremely low birth 
weight/ or infant, premature/ or infant, extremely 
premature/ or (low adj3 gestational age).ti,ab. Or 
(small adj3 gestational age).ti,ab. Or 
neonat*.ti,ab. Or premature*.ti,ab. or 
preterm.ti,ab. or low birth weight.ti,ab. or (VLBW 
or ELBW).ti,ab. 
AND 
respiratory distress syndrome, newborn/ 
 
Not: exp animal/ not human/ 
Not: limit to (case reports or comment or editorial 
or historical article or letter) 
Limit to (yr=2010-current and English) 
505 
 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
Table 1: Various definitions of BPD identified in literature 
 
 
Reference Definition 
Northway, 
1967(6) 
Prolongation of the healing phase of respiratory-distress syndrome 
combined with a generalized pulmonary oxygen toxicity involving mucosal, 
alveolar and vascular tissues. 
Tooley, 1979(7) At 30 days of postnatal age, an infant who has any radiologic abnormality 
of the lung parenchyma plus at least of one the following: (1) an oxygen 
tension in arterial blood breathing air of 60 mm of Hg (7.99 kPa) or less, 
(2) carbon dioxide tension in arterial blood of more than 45 mm of Hg 
(5.99 kPa), and /or (3) oxygen dependence (i.e. requires an FiO2 of more 
than 0.21). 
Bancalari, 
1979(9) 
An infant who has: (1) required intermittent positive pressure ventilation 
during the first week of life and for a minimum of three days, (2) developed 
clinical signs of chronic respiratory disease characterized by tachypnea, 
intercostal and subcostal retraction, and rales on auscultation, all 
persisting for longer than 28 days, (3) required supplemental oxygen for 
more than 28 days to maintain a PaO2 over 50 mm Hg, and (4) chest 
radiograph showed persistent strands of densities in both lungs, 
alternating with areas of normal or increased lucency. 
Shennan,1988(8) Requirement for additional oxygen at 36 weeks post-menstrual age (PMA) 
in infants born with a birth weight of less than 1,500 g. 
National Institute 
of Child Health 
and Human 
Development 
(NICHD) 
2001(12) 
Gestational age <32 weeks Gestational age ≥ 32 weeks 
Time point of assessment: 36 
weeks PMA or discharge to home, 
whichever comes first 
Time point of assessment: >28 d 
but <56 d postnatal age or 
discharge to home, whichever 
comes first 
 
Treatment with oxygen > 21% for at least 28 days and: 
Mild BPD: Breathing room air at 36 
weeks PMA or discharge, 
whichever comes first 
Moderate BPD: Need for <30% 
oxygen at 36 weeks PMA or 
discharge, whichever comes first 
Severe BPD: Need for ≥ 30% 
oxygen and/or positive pressure, 
(positive pressure ventilation or 
NCPAP) at 36 weeks PMA or 
discharge, whichever comes first. 
Mild BPD: Breathing room air at 56 
days postnatal age or discharge, 
whichever comes first 
Moderate BPD: Need for <30% 
oxygen at 56 days postnatal age or 
discharge, whichever comes first 
Severe BPD: Need for ≥ 30% 
oxygen and/or positive pressure, 
(positive pressure ventilation or 
NCPAP) at 56 days postnatal age 
or discharge, whichever comes first. 
Walsh, 2004(16)  Same as NICHD definition, but infants in supplemental oxygen <0.30 
underwent an oxygen challenge test with timed stepwise reduction to 
room air. Those who failed the reduction test were diagnosed with BPD. 
Vermont Oxford 
Network(20) 
Infants who required supplemental oxygen at 36 weeks PMA. Infants who 
went home requiring supplemental oxygen at 34 to 36 weeks PMA were 
classified as having BPD. For infants who were discharged before 34 
weeks, the BPD status was considered unknown. 
ICD 
770.7/P27.1(21) 
ICD 770.7: Chronic respiratory disease arising in the perinatal period. 
ICD P27.1: Bronchopulmonary dysplasia originating in the perinatal 
period. 
Other definitions 
used 
Oxygen / respiratory support at 28 days 
Oxygen / respiratory support at 36 weeks or at discharge 
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BPD, Bronchopulmonary Dysplasia; FiO2, Fraction of Inspired Oxygen; PaO2, Partial 
Pressure Arterial Oxygen; Hg, Mercury; NICHD, National Institute of Child Health and 
Human Development ;PMA, Post-Menstrual Age; ICD, International Classification of 
Diseases; NCPAP, Nasal Continuous Positive Airway Pressure;  
 
Table 2: Characteristics of studies included in the review 
Characteristic Category 
BPD not 
defined (n=192) 
n (%) 
BPD defined 
(n=628) 
n (%) 
P 
Continent of 
study 
Europe 73 (22) 253 (78) 
0.44 
North America 76 (26) 217 (74) 
Asia 26 (19) 108 (81) 
Oceania 8 (22) 28 (78) 
Transcontinental 4 (25) 12 (75) 
South America 3 (25) 9 (75) 
Africa 2 (67) 1 (33) 
Study sites 
Multicenter 74 (24) 232 (76) 
0.73 
Single 118 (23) 396 (77) 
Year of 
publication 
2010 26 (24) 82 (76) 
0.57 
2011 34 (27) 92 (73) 
2012 25 (18) 115 (82) 
2013 35 (25) 104 (75) 
2014     35 (24) 108 (76) 
2015 37 (23) 127 (77) 
Type of study* 
Retrospective cohort 92 (24) 290 (76) 
<0.01 
Prospective cohort 38 (23) 129 (77) 
Randomized controlled 
trial/Clinical trial 
40 (30) 91 (70) 
Case-control 13 (14) 83 (86) 
Cross-sectional  2 (10) 18 (90) 
Survey/questionnaire 7 (54) 6 (46) 
Case series (including 
before-after design) 
0 (0) 11 (100) 
Primary outcome 
BPD in report 
Yes 73 (17) 348 (83) 
<0.01 
No 119 (30) 280 (70) 
*One study had a mixed design.  
BPD, Bronchopulmonary dysplasia 
 
Oxygen at 28 days OR oxygen at 36 weeks/discharge 
Oxygen at 28 days AND oxygen at 36 weeks/discharge 
Modified NICHD definitions: modified based on different components of 
the original definition 
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Table 3: Characteristics of studies that defined BPD (n=628) 
Characteristic Type Frequency Percent 
Definition used 
Oxygen at 36 weeks PMA 284 45.2 
NICHD criteria 188 29.9 
Oxygen at 28 days 53 8.4 
Oxygen/respiratory support at 36 weeks 
PMA 
37 5.9 
Oxygen at 36 weeks PMA and/or 
oxygen at 28 days 
22 3.5 
Modified NICHD 20 3.2 
Other 8 1.3 
Vermont Oxford Network definition 7 1.1 
Combination of definition 4 0.6 
ICD code 770.7 3 0.5 
Oxygen/respiratory support at 28 days 2 0.3 
Incorporation of 
physiological test 
No 588 93.6 
Yes 37 5.9 
Partly 3 0.5 
Accounting of death before 
definition criteria met 
No 596 94.9 
Yes 32 5.1 
Severity of BPD 
categorized 
No 440 70.1 
Yes 188 29.9 
BPD, Bronchopulmonary Dysplasia; NICHD, National Institute of Child Health and Human 
Development; PMA, Post-Menstrual Age; ICD, International Classification of Diseases 
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Table 4: Studies comparing different definitions of BPD incidences 
Author Population Definition Incidence 
Palta 1998(22)  Neonates ≤1500g (n=272) Tooley(7) 37.9%  
Shennan(8) 23.0% 
Gregoire 
1998(23) 
24-28 weeks gestation who 
survived to discharge and 
were followed (n=217) 
Tooley(7) 65% 
Shennan(8) 43% 
Bancalari 
2003(24) 
Alive at 28 days, 500 – 
1000g; GA 23-32 weeks 
(n=1266) 
Oxygen during all of first 28 days  5.9% 
On oxygen at 28 days  57.2% 
On oxygen for ≥ 28 days 47.1% 
Shennan(8) 25% 
NICHD(12) 22.8% 
Sahni 2005(25)  For neonates <1251g BW 
(27.3 ± 2.3 weeks GA) 
(n=230 studied at 28 days, 
n=237 studied at 36 weeks 
PMA) 
Tooley(7) 21.1% 
Shennan(8) 7.4% 
Mild BPD(12) 13.5% 
Moderate BPD(12) 4.8% 
Severe BPD(12) 2.6% 
Ehrenkranz 
2005(14)  
GA: <32 weeks and BW <1 
kg (n=4866; 3848 had follow 
up data) 
Tooley(7) 77% 
Tooley(7) + x-ray changes 59% 
Shennan(8) 44% 
Shennan(8) + x-ray changes 39% 
NICHD(12) 76%; Mild (30%), Moderate (30%), 
Severe (16%) 
Bancalari 
2006(13)  
 
GA: 23-30 weeks, alive at 36 
weeks PMA, (n=441) 
On oxygen for all first 28 days  10% 
Tooley(7)/Bancalari(9)  55% 
On oxygen for ≥ 28 days during 
stay  
50% 
NICHD(12) 20% 
Shima 
2013(26)  
Neonates <32 weeks GA, 
<1550g (n=306) 
Tooley(7) 42%  
NICHD(12) – moderate and severe 17% 
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Parad 
2015(27) 
GA: 23-28 weeks and BW 
<1335g (n= 76) – derivation 
cohort 
Bancalari(9) 84% 
Shennan(8) 59% 
GA: 23-28 weeks and BW 
<1459g (n= 227) – validation 
cohort 
Bancalari(9) 84% 
Shennan(8) 63% 
Van Rossem 
2015(19)  
<32 weeks gestation who 
needed respiratory support 
between 25 and 32 days of 
postnatal age (n=170) 
Shennan(8) ascertained from 
national registry (PRN) 
55% 
BPD according to algorithm 
VON(20) 
31% (21% missing information) 
BPD according to NICHD(12) 55%; 
Mild BPD: 17% 
Moderate BPD: 16% 
Severe BPD: 22% 
Poindexter 
2015(15)  
Infants born between 230/7 
and 286/7 weeks (n=765) 
Shennan(8)  BPD: 41%; Unclassified: 11% 
NICHD(12) BPD: 59% (Mild-20%, Moderate-12%, 
Severe- 28%); Unclassified: 2% 
Oxygen test added to NICHD(12) 
criteria 
BPD: 32%; Unclassified: 16% 
Modified Shennan et al(8) (no BPD 
if discharged home before 36 
weeks in room air) 
BPD: 41%; Unclassified: 11% 
Modified NICHD(12) (without the 
requirement for at least 28 days of 
supplemental oxygen) 
BPD: 42% (moderate: 12%; severe: 
30%); Unclassified: 2% 
BPD, Bronchopulmonary Dysplasia; BW, Birth Weight; GA,  Gestational Age, PMA, Post-Menstrual Age; NICHD, National Institute of Child 
Health and Human Development; PRN, National Perinatal Registry; VON, Vermont Oxford Network 
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Table 5: Studies comparing different definitions of BPD and their correlation to long-term adverse outcomes 
Author, Follow 
up age, Study 
Population 
Definition Long-Term Outcome 
Measure 
Sensitivity 
(%) 
Specificity 
(%) 
PPV 
(%) 
NPV 
(%) 
Other statistics 
Palta 1998(22), 
5 years of age, 
N=272 
Tooley(7) Diagnosis of asthma 52 66 29 83 AOR 1.3; 95% CI 0.6-2.8 
Shennan(8) 43 82 40 84 AOR 2.7; 95% CI 1.3-5.7 
Tooley(7) Respiratory 
hospitalization 
58 68 37 83 AOR 2.8; 95% CI 1.4-5.8 
Shennan(8) 38 82 40 80 AOR 3.6; 95% CI 1.7-7.6 
Gregoire 
1998(23),18.5 
months of age, 
N=217 
Tooley(7) Hospitalization due to 
respiratory cause 
69 37 33 72  
Shennan(8) 53 62 39 74  
Tooley(7) Developmental 
quotient < 82 
72 37 20 86  
Shennan(8) 58 60 24 86  
Tooley(7) Severe cerebral palsy 69 36 16 38  
Shennan(8) 50 58 17 87  
Davis 2002(28), 
18 months of 
age, N=809 
Tooley(7) Pulmonary outcome* 67 54 62 58 Accuracy: 61% 
Neurosensory 
outcome** 
67 47 39 74 Accuracy: 54% 
Shennan(8) Pulmonary outcome* 46 82 75 57 Accuracy: 63% 
Neurosensory 
outcome** 
45 72 45 72 Accuracy: 63% 
Ehrenkranz 
2005(14), 18-22 
months of age, 
N= 3848 
Tooley(7) Use of diuretics or 
bronchodilators  
82 26 38 73  
Tooley(7) + x-ray 
changes 
68 44 40 72 
Shennan(8) 54 62 44 71 
Shennan(8) + x-ray 
changes 
49 67 45 71 
NICHD(12) 82 26 38 73 
Tooley(7) Rehospitalization due 82 25 32 76  
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Tooley(7) + x-ray 
changes 
to pulmonary causes 67 43 34 75 
Shennan(8) 52 60 36 74 
Shennan(8) + x-ray 
changes 
47 65 37 74 
NICHD(12) 82 25 32 76 
Parad 
2015(27), 24 
months 
corrected age, 
N=76;N=227 
Bancalari(9) Respiratory hospital 
admission 
NC NC NC NC AOR 3.89; 95% CI 0.45-33.6; 
AUC 0.55 
Shennan(8) NC NC NC NC AOR 1.58; 95% CI 0.5-5.0; 
AUC 0.55 
Bancalari(9) Any cough, wheeze, 
and/or use of 
respiratory 
medications  
NC NC NC NC AOR 0.94; 95% CI 0.38-2.32; 
AUC 0.5 
Shennan(8) NC NC NC NC AOR 1.41; 95% CI 0.69-2.9; 
AUC 0.54 
BPD, Bronchopulmonary Dysplasia; GA,  Gestational Age, PMA, Post-Menstrual Age; BW, Birth weight; OR, Odds Ratio; NICHD, National 
Institute of Child Health and Human Development; VON, Vermont Oxford Network; PPV, Positive Predictive Value; NPV, Negative Predictive 
Value; AOR, Adjusted Odds Ratio; NC, Not calculable; AUC, Area Under the Curve 
*Abnormal pulmonary outcome= death from any cause; need for oxygen therapy or ventilation after discharge home; need for respiratory 
medication (including inhaled corticosteroids, systemic corticosteroids, and bronchodilators) for a total of more than 2 months; and readmission 
to hospital because of respiratory illness 
** Abnormal neurosensory outcome = death from any cause; cerebral palsy; cognitive delay; hearing loss requiring amplification; and bilateral 
blindness 
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